Clinical Trials Logo

Progeria clinical trials

View clinical trials related to Progeria.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT00916747 Active, not recruiting - Progeria Clinical Trials

Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria

Start date: August 2009
Phase: Phase 2
Study type: Interventional

Hutchinson-Gilford Progeria Syndrome (Progeria) is a rare autosomal disease that results in premature death at a median age of 13 years due to cardiovascular and cerebralvascular compromise. The mutation for this disease has been identified and results in a mutant form of lamin A that cannot be de-farnesylated. This study evaluates the combination of pravastain (a statin), lonafarnib (a farnesyltransferase inhibitor) and zoledronic acid (a bisphosphonate) in an open label phase II efficacy trial in children with Progeria. These agents all target farnesylation pathways at different points. Patients with genetically confirmed progeria will be eligible for this protocol. Treatment will be initiated for 24 months duration. Clinical and biologic parameters will be examined to assess response.